June 7, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend in shares for the year 2021 has been determined. The exchange ratio is 1 new common share for every 27.3184 existing common shares. This ratio was based on
LONDON and AMSTERDAM, June 07, 2022 (GLOBE NEWSWIRE) — Trust Payments, the disruptive leader in fintech specialising in frictionless payments and value-added services, announced today at Money20/20 Europe a multi-year partnership with Feedzai, the world’s first RiskOps platform for financial risk management. Using Feedzai, a key market leader in safeguarding
June 7, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Willem (Wim) Appelo will join Philips’ Executive Committee, effective July 18, 2022, and succeed Sophie Bechu as Chief Operations Officer per October 1, 2022. Mr. Appelo will report to Philips CEO Frans van […]
Keeping an eye on the world market: crop.zone strengthens its capital base for serial production Dirk Vandenhirtz CEO – Founder AACHEN, Germany, June 07, 2022 (GLOBE NEWSWIRE) — Good news for herbicide-free agriculture. crop.zone, manufacturer of the volt.fuel Electrical Weeding System, has significantly strengthened its capital base for entering into
GHENT, Belgium, June 07, 2022 (GLOBE NEWSWIRE) — MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of preclinical research relating to its ongoing program in non-alcoholic fatty liver disease (NAFLD), with a 9-strain live bacterial consortium resulting from its proprietary and unique CORAL®
Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV® test as part of routine care Groundbreaking host-response test distinguishes between bacterial and viral infection in just 15 minutes Prompt differentiation enables early treatment to prevent deterioration and reduction of unnecessary prescription of antibiotics
–Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors –Toripalimab continues to demonstrate synergy as the cornerstone in innovative combination therapies SHANGHAI, China, June 07, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180),
